Assignee
EDITAS MEDICINE INC
US·49 granted patents·73 pending applications·255 citations·filing 2014–2025
Top patents by PatentIndex Score
122 records- 0198US10190137B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2017·Granted Jan 29, 2019·37 cites·26 claims
- 0298US9834791B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2014·Granted Dec 5, 2017·97 cites·30 claims
- 0397US11390887B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2020·Granted Jul 19, 2022·6 cites·8 claims
- 0497US10640788B2CRISPR-related methods and compositions with governing gRNAsEDITAS MEDICINE INC·Filed 2019·Granted May 5, 2020·18 cites·25 claims
- 0595US10253312B2CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2018·Granted Apr 9, 2019·13 cites·29 claims
- 0695US9963719B1Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2017·Granted May 8, 2018·15 cites·14 claims
- 0794US9938521B2CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2015·Granted Apr 10, 2018·12 cites·39 claims
- 0893US12234449B2CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2022·Granted Feb 25, 2025·1 cites·17 claims
- 0992US11028388B2CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosaEDITAS MEDICINE INC·Filed 2015·Granted Jun 8, 2021·7 cites·22 claims
- 1092US10006054B1Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2018·Granted Jun 26, 2018·6 cites·18 claims
- 1191US10428319B2Engineered Cas9 nucleasesEDITAS MEDICINE INC·Filed 2018·Granted Oct 1, 2019·9 cites·20 claims
- 1290US12201699B2Compositions and methods for promoting homology directed repairEDITAS MEDICINE INC·Filed 2021·Granted Jan 21, 2025·1 cites·17 claims
- 1390US11268086B2CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2019·Granted Mar 8, 2022·3 cites·41 claims
- 1490US11236313B2Cas9 fusion molecules, gene editing systems, and methods of use thereofEDITAS MEDICINE INC·Filed 2017·Granted Feb 1, 2022·4 cites·14 claims
- 1589US11390884B2Optimized CRISPR/cas9 systems and methods for gene editing in stem cellsEDITAS MEDICINE INC·Filed 2016·Granted Jul 19, 2022·7 cites·16 claims
- 1686US12264331B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2023·Granted Apr 1, 2025·0 cites·26 claims
- 1785US11339437B2Compositions and methods for treating CEP290-associated diseaseEDITAS MEDICINE INC·Filed 2017·Granted May 24, 2022·3 cites·117 claims
- 1884US11566263B2Compositions and methods for treating CEP290 associated diseaseEDITAS MEDICINE INC·Filed 2017·Granted Jan 31, 2023·3 cites·28 claims
- 1984US11098297B2Engineered Cas9 nucleasesEDITAS MEDICINE INC·Filed 2019·Granted Aug 24, 2021·2 cites·13 claims
- 2084US11028411B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2019·Granted Jun 8, 2021·1 cites·28 claims
- 2184US2025288698A1Compositions and methods for promoting homology directed repairEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 2283US12359223B2Systems and methods for modulating chromosomal rearrangementsEDITAS MEDICINE INC·Filed 2019·Granted Jul 15, 2025·2 cites·18 claims
- 2383US11001844B2CRISPR/Cas-related methods and compositions for treating herpes simplex virusEDITAS MEDICINE INC·Filed 2018·Granted May 11, 2021·2 cites·26 claims
- 2482US11242525B2CRISPR/CAS-related methods and compositions for treating sickle cell diseaseEDITAS MEDICINE INC·Filed 2015·Granted Feb 8, 2022·2 cites·28 claims
- 2580US2022389460A1CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
- 2680US2024067992A1Human hematopoietic stem cell having a modified bcl11a gene and methods of making the cellEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 2778US11692205B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2021·Granted Jul 4, 2023·0 cites·6 claims
- 2878US11141493B2Compositions and methods for treating CEP290-associated diseaseEDITAS MEDICINE INC·Filed 2018·Granted Oct 12, 2021·2 cites·35 claims
- 2976US2026034247A1Compositions and methods for treating cep290-associated diseaseEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 3075US11680268B2Methods for improving CRISPR/Cas-mediated genome-editingEDITAS MEDICINE INC·Filed 2015·Granted Jun 20, 2023·1 cites·17 claims
- 3175US2024294917A1Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)EDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3274US2023365980A1Methods for improving crispr/cas-mediated genome-editingEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3373US12049651B2Cas9 fusion molecules, gene editing systems, and methods of use thereofEDITAS MEDICINE INC·Filed 2021·Granted Jul 30, 2024·0 cites·18 claims
- 3473US2024084348A1Nucleic acid mutagenesis methodsEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3572US12545912B2CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosaEDITAS MEDICINE INC·Filed 2021·Granted Feb 10, 2026·0 cites·20 claims
- 3672US12297466B2Engineered Cas9 nucleasesEDITAS MEDICINE INC·Filed 2021·Granted May 13, 2025·0 cites·6 claims
- 3772US2024117383A1Selection by essential-gene knock-inEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3872US2024132877A1Genome editing systems comprising repair-modulating enzyme molecules and methods of their useEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3972US2024167059A1Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sitesEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4071US2023313174A1Emulsion-based screening methodsEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
- 4171US2023340456A1Use of exonucleases to improve crispr/cas-mediated genome editingEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4270US10494649B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2018·Granted Dec 3, 2019·0 cites·6 claims
- 4370US2026035693A1Systems and methods for the treatment of hemoglobinopathiesEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 4470US2024141386A1Compositions and methods for treating cep290 associated diseaseEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4570US2024360471A1Crispr/cas-related methods and compositions for treating beta hemoglobinopathiesEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4670US2025179488A1Systems and methods for the treatment of hemoglobinopathiesEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 4769US11834649B2CRISPR/CAS-related methods and compositions for treating herpes simplex virusEDITAS MEDICINE INC·Filed 2021·Granted Dec 5, 2023·0 cites·21 claims
- 4868US2022273818A1Compositions and methods for treating cep290-associated diseaseEDITAS MEDICINE INC·Filed 2021·Application pending·0 cites
- 4968US2025297288A1Genome editing of b cellsEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 5068US2023026726A1Crispr/cas-related methods and compositions for treating sickle cell diseaseEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 122 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →